Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer.
Zapata Dongo RJ et al.
Frontiers in Pharmacology, 2025
Pathway-based, reaction-specific annotation of disease variants for elucidation of molecular phenotypes.
Orlic-Milacic M et al.
Database : the Journal of Biological Databases and Curation, 2024
Integrated analysis of the clinical consequence and associated gene expression of ALK in ALK-positive human cancers.
Saifullah et al.
Heliyon, 2022
Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools.
Garcia-Prieto CA et al.
Bioinformatics (oxford, England), 2022
Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Lee B et al.
Frontiers in Oncology, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
The role of anaplastic lymphoma kinase in pediatric cancers.
Takita J
Cancer Science, 2017
New insights into the genetics of neuroblastoma.
Sridhar S et al.
Molecular Diagnosis & Therapy, 2013
Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.
Chand D et al.
Disease Models & Mechanisms, 2013
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
Oncogenic anaplastic lymphoma kinase (ALK) mutation in neuroblastomas and other pediatric tumors.
Kwon MJ et al.
Pathology, Research and Practice, 2011
Emerging importance of ALK in neuroblastoma.
Azarova AM et al.
Seminars in Cancer Biology, 2011
Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.
Bossi RT et al.
Biochemistry, 2010
Genetics and genomics of neuroblastoma.
Capasso M et al.
Cancer Treatment and Research, 2010
Anaplastic lymphoma kinase: signalling in development and disease.
Palmer RH et al.
The Biochemical Journal, 2009
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.
Webb TR et al.
Expert Review of Anticancer Therapy, 2009
Activating mutations in ALK provide a therapeutic target in neuroblastoma.
George RE et al.
Nature, 2008